A Phase 3 interventional study of Gepotidacin and Ceftriaxone in Gonorrhea, sponsored by GlaxoSmithKline. Completed at 51 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.
Among the 98 studies in Gonorrhea with a site in United States, this one is the 26th largest by enrollment of the 76 interventional ones that give a count, is one of 10 that started in 2019, is one of 9 in phase 3, and was the 69th registered.
168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.
Browse Gonorrhea studies →11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Women only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16–24
Tulane University · Sites in United States
Ages 15–26 · Healthy volunteers
Queen's Medical Center · Sites in United States
Ages 14+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 11 · Phase 4 7
First in 1999; this study’s year is marked. 10 started in 2019.
This study's enrollment of 628 is above the median of 380 across 126 interventional studies indexed under Gonorrhea.
Median enrollment 341 across the 76 interventional studies, 907 across the 21 observational. Of the 85 that completed or were terminated, 37 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 98 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Gonorrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Gonorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies in Gonorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae (N. gonorrhoeae) in adolescent and adult participants. In this study, participants will be randomly assigned to receive either oral gepotidacin or IM ceftriaxone plus oral azithromycin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 10 to 12 hours after the first dose.
Drug: Gepotidacin
Participants will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
Drug: Ceftriaxone · Drug: Azithromycin
Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)
Urogenital specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit
Rectal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit
Pharyngeal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
Time frame: Up to 21 days
Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Neutrophils, Platelets, Lymphocytes, Monocytes, Neutrophils and Nucleated Erythrocytes
Blood samples were collected for the assessment of change from baseline in hematology parameters: basophils, eosinophil, leukocytes, neutrophils, platelets, lymphocytes, monocytes, neutrophils and nucleated erythrocytes. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb)
Blood samples were collected for the assessment of change from baseline in hematology parameters: mean corpuscular hemoglobin concentration and hemoglobin. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected for the assessment of change from baseline in hematology parameter: hematocrit. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected for the assessment of change from baseline in hematology parameter: red blood cell (RBC) count. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular hemoglobin (MCH). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular volume (MCV). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Clinical Chemistry Parameters: Urea Nitrogen (UN), Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium
Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: urea nitrogen (UN), glucose, calcium, chloride, sodium, magnesium and potassium. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: bilirubin, direct bilirubin and creatinine levels. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: albumin and protein. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP)
Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Number of Participants With Urinalysis Dipstick Results
Urine samples were collected for urinalysis: Glucose, Protein, Occult Blood and Ketones. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Small, Moderate, Large, Positive, 5 milligram per deciliter (mg/dL), 20 mg/dL, 30 mg/dL 50 mg/dL, 100 mg/dL, 150 mg/dL and \>=500 mg/dL indicating concentrations in the urine sample. In the row title (Glucose, Baseline, Negative), Glucose indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Absolute Values in Specific Gravity of Urine
Urine samples were collected from participants to assess urine specific gravity. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Absolute Values in Potential of Hydrogen (pH) of Urine
Urine samples were collected from participants to assess urine pH. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Vital Sign: Pulse Rate
Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
Change From Baseline in Vital Sign: Temperature
Temperature was measured after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)
| Milestone | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Started | 314 | 314 |
| Safety population | 309 | 313 |
| Microbiological itt (micro-itt) population | 202 | 204 |
| Micro-itt rectal population | 26 | 15 |
| Micro-itt pharyngeal population | 18 | 17 |
| Completed | 294 | 295 |
| Not completed | 20 | 19 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Lost to follow-up | 10 | 14 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Participant did not receive ip | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Randomized in error/ mistake | 2 | 0 |
| Withdrew: Eligibility criteria unable to evaluate | 1 | 0 |
Urogenital specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
| Participants | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Microbiological success | 187 | 186 |
| Microbiological failure, BP | 0 | 0 |
| Microbiological failure, UTD | 15 | 18 |
Rectal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
| Participants | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Microbiological success | 26 | 12 |
| Microbiological failure, BP | 0 | 0 |
| Microbiological failure, UTD | 0 | 3 |
Pharyngeal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.
| Participants | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Microbiological success | 14 | 16 |
| Microbiological failure, BP | 2 | 0 |
| Microbiological failure, UTD | 2 | 1 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
| Participants | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Any TEAEs | 230 | 104 |
| Any SAEs | 1 | 0 |
Blood samples were collected for the assessment of change from baseline in hematology parameters: basophils, eosinophil, leukocytes, neutrophils, platelets, lymphocytes, monocytes, neutrophils and nucleated erythrocytes. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per liter (10^9 cells/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Basophils, Baseline (Day 1) | 0.044 ± 0.0196 | 0.045 ± 0.0222 |
| Basophils, CFB to TOC | 0.001 ± 0.0167 | 0.000 ± 0.0152 |
| Eosinophils, Baseline (Day 1) | 0.154 ± 0.2117 | 0.160 ± 0.1384 |
| Eosinophils, CFB to TOC | 0.009 ± 0.1289 | 0.018 ± 0.0827 |
| Leukocytes, Baseline (Day 1) | 7.143 ± 2.2808 | 7.507 ± 2.2045 |
| Leukocytes, CFB to TOC | -0.811 ± 1.8536 | -1.267 ± 1.9362 |
| Neutrophils, Baseline (Day 1) | 4.443 ± 1.9621 | 4.774 ± 1.9355 |
| Neutrophils, CFB to TOC | -1.062 ± 1.7309 | -1.473 ± 1.8860 |
| Platelets, Baseline (Day 1) | 260.3 ± 61.79 | 268.4 ± 69.26 |
| Platelets, CFB to TOC | 10.2 ± 32.14 | 9.7 ± 34.94 |
| Lymphocytes, Baseline (Day 1) | 1.934 ± 0.5941 | 1.948 ± 0.6321 |
| Lymphocytes, CFB to TOC | 0.277 ± 0.5205 | 0.245 ± 0.5511 |
| Monocytes, Baseline (Day 1) | 0.559 ± 0.2209 | 0.572 ± 0.1877 |
| Monocytes, CFB to TOC | -0.034 ± 0.1917 | -0.053 ± 0.1782 |
| Nucleated Erythrocytes, Baseline (Day 1) | 0.002 ± 0.0047 | 0.001 ± 0.0038 |
| Nucleated Erythrocytes, CFB to TOC | 0.000 ± 0.0070 | 0.001 ± 0.0059 |
Blood samples were collected for the assessment of change from baseline in hematology parameters: mean corpuscular hemoglobin concentration and hemoglobin. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Grams per liter (g/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| MCHC, Baseline (Day 1) | 318.5 ± 16.27 | 318.8 ± 16.12 |
| MCHC, CFB to TOC | 2.4 ± 10.67 | 0.3 ± 11.27 |
| Hb, Baseline (Day 1) | 149.1 ± 12.83 | 149.2 ± 12.58 |
| Hb, CFB to TOC | 0.00 ± 6.70 | 0.6 ± 6.92 |
Blood samples were collected for the assessment of change from baseline in hematology parameter: hematocrit. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Percentage | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 0.4691 ± 0.04205 | 0.4687 ± 0.04104 |
| CFB to TOC | -0.0038 ± 0.02526 | 0.0012 ± 0.02666 |
Blood samples were collected for the assessment of change from baseline in hematology parameter: red blood cell (RBC) count. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Trillion cells per liter (10^12 cells/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 4.911 ± 0.4722 | 4.926 ± 0.4601 |
| CFB to TOC | 0.003 ± 0.2261 | 0.019 ± 0.2332 |
Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular hemoglobin (MCH). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Picograms (pg) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 30.46 ± 1.978 | 30.38 ± 1.987 |
| CFB to TOC | -0.03 ± 0.451 | 0.00 ± 0.594 |
Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular volume (MCV). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Femtoliters (fL) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 95.79 ± 6.266 | 95.43 ± 6.760 |
| CFB to TOC | -0.85 ± 3.104 | -0.12 ± 3.084 |
Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: urea nitrogen (UN), glucose, calcium, chloride, sodium, magnesium and potassium. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Millimoles per liter (mmol/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| UN, Baseline (Day 1) | 4.793 ± 1.4293 | 4.800 ± 1.4669 |
| UN, CFB to TOC | 0.190 ± 1.1640 | 0.282 ± 1.1920 |
| Glucose, Baseline | 5.049 ± 1.0557 | 5.090 ± 1.1183 |
| Glucose, CFB to TOC | 0.227 ± 0.9425 | 0.064 ± 0.9684 |
| Calcium, Baseline (Day 1) | 2.387 ± 0.0986 | 2.387 ± 0.0954 |
| Calcium, CFB to TOC | -0.009 ± 0.0852 | -0.015 ± 0.0871 |
| Chloride, Baseline (Day 1) | 101.7 ± 2.26 | 101.7 ± 2.30 |
| Chloride, CFB to TOC | 0.7 ± 2.57 | 0.5 ± 2.40 |
| Sodium, Baseline (Day 1) | 139.6 ± 2.11 | 139.6 ± 2.02 |
| Sodium, CFB to TOC | 0.2 ± 2.19 | 0.1 ± 2.44 |
| Magnesium, Baseline (Day 1) | 0.854 ± 0.0612 | 0.855 ± 0.0637 |
| Magnesium, CFB to TOC | -0.003 ± 0.0604 | -0.004 ± 0.0584 |
| Potassium, Baseline (Day 1) | 4.29 ± 0.323 | 4.30 ± 0.332 |
| Potassium, CFB to TOC | -0.04 ± 0.336 | -0.03 ± 0.345 |
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: bilirubin, direct bilirubin and creatinine levels. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Micromoles per liter (umol/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Bilirubin, Baseline (Day 1) | 8.54 ± 5.861 | 7.71 ± 4.806 |
| Bilirubin, CFB to TOC | -0.05 ± 5.025 | -0.14 ± 3.914 |
| Direct Bilirubin, Baseline (Day 1) | 3.83 ± 1.248 | 3.76 ± 1.210 |
| Direct Bilirubin, CFB to TOC | -0.02 ± 0.897 | 0.01 ± 0.876 |
| Creatinine, Baseline (Day 1) | 75.9 ± 34.12 | 75.0 ± 20.63 |
| Creatinine, CFB to TOC | -0.2 ± 34.08 | 2.6 ± 9.52 |
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: albumin and protein. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Grams per liter (g/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Albumin, Baseline (Day 1) | 46.9 ± 3.12 | 46.8 ± 3.19 |
| Albumin, CFB to TOC | -0.3 ± 2.35 | -0.3 ± 2.67 |
| Protein, Baseline (Day 1) | 73.1 ± 4.80 | 73.3 ± 4.85 |
| Protein, CFB to TOC | -0.5 ± 3.86 | -0.5 ± 4.02 |
Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| International units per Liter (IU/L) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| AST, Baseline (Day 1) | 24.4 ± 15.30 | 24.2 ± 16.29 |
| AST, CFB to TOC | 2.8 ± 19.51 | 0.9 ± 13.25 |
| ALT, Baseline (Day 1) | 23.7 ± 18.78 | 23.7 ± 14.35 |
| ALT, CFB to TOC | 1.4 ± 12.59 | 1.1 ± 7.64 |
| ALP, Baseline (Day 1) | 76.0 ± 20.86 | 77.1 ± 26.53 |
| ALP, CFB to TOC | -0.4 ± 7.73 | -1.5 ± 7.80 |
Urine samples were collected for urinalysis: Glucose, Protein, Occult Blood and Ketones. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Small, Moderate, Large, Positive, 5 milligram per deciliter (mg/dL), 20 mg/dL, 30 mg/dL 50 mg/dL, 100 mg/dL, 150 mg/dL and \>=500 mg/dL indicating concentrations in the urine sample. In the row title (Glucose, Baseline, Negative), Glucose indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Glucose, Baseline (Day 1), Negative | 296 | 305 |
| Glucose, Baseline (Day 1), 150 mg/dL | 0 | 0 |
| Glucose, Baseline (Day 1), >=500 mg/dL | 3 | 2 |
| Glucose, TOC, Negative | 284 | 283 |
| Glucose, TOC, 150 mg/dL | 1 | 1 |
| Glucose, TOC, >=500 mg/dL | 2 | 1 |
| Ketones, Baseline (Day 1), Negative | 288 | 300 |
| Ketones, Baseline (Day 1), 5 mg/dL | 10 | 7 |
| Ketones, Baseline (Day 1), 20 mg/dL | 1 | 0 |
| Ketones, TOC, Negative | 279 | 279 |
| Ketones, TOC, 5 mg/dL | 7 | 6 |
| Ketones, TOC, 20 mg/dL | 1 | 0 |
| Occult Blood, Baseline (Day 1), Negative | 202 | 192 |
| Occult Blood, Baseline (Day 1), Small | 77 | 91 |
| Occult Blood, Baseline (Day 1), Moderate | 18 | 19 |
| Occult Blood, Baseline (Day 1), Large | 2 | 5 |
| Occult Blood, TOC, Negative | 251 | 252 |
| Occult Blood, TOC, Small | 30 | 24 |
| Occult Blood, TOC, Moderate | 3 | 6 |
| Occult Blood, TOC, Large | 3 | 3 |
| Protein, Baseline (Day 1), Negative | 212 | 210 |
| Protein, Baseline (Day 1), 30 mg/dL | 79 | 83 |
| Protein, Baseline (Day 1), 100 mg/dL | 8 | 13 |
| Protein, Baseline (Day 1), >=500 mg/dL | 0 | 1 |
| Protein, TOC, Negative | 239 | 244 |
| Protein, TOC, 30 mg/dL | 46 | 37 |
| Protein, TOC, 100 mg/dL | 2 | 4 |
| Protein, TOC, >=500 mg/dL | 0 | 0 |
Urine samples were collected from participants to assess urine specific gravity. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Ratio | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 1.0211 ± 0.00750 | 1.0207 ± 0.00747 |
| TOC | 1.0211 ± 0.00720 | 1.0216 ± 0.00748 |
Urine samples were collected from participants to assess urine pH. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| pH | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 5.6 ± 0.69 | 5.6 ± 0.70 |
| TOC | 5.5 ± 0.64 | 5.4 ± 0.62 |
SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Millimeters of mercury (mmHg) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| SBP, Baseline (Day 1) | 123.9 ± 13.69 | 125.1 ± 14.41 |
| SBP, CFB to TOC | -0.4 ± 12.61 | -0.5 ± 12.86 |
| DBP, Baseline (Day 1) | 76.7 ± 10.77 | 77.2 ± 10.50 |
| DBP, CFB to TOC | 0.1 ± 9.10 | -0.9 ± 9.54 |
Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Beats per minute | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 73.0 ± 12.24 | 72.8 ± 12.20 |
| CFB to TOC | 2.2 ± 12.44 | 2.4 ± 12.33 |
Temperature was measured after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Celsius (C) | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Baseline (Day 1) | 36.45 ± 0.395 | 36.44 ± 0.457 |
| CFB to TOC | -0.03 ± 0.381 | -0.06 ± 0.485 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 through the final follow-up visit (up to 21Days).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gepotidacin | 0/309 (0%) | 1/309 (0.3%) | 230/309 (74.4%) |
| Ceftriaxone Plus Azithromycin | 0/313 (0%) | 0/313 (0%) | 81/313 (25.9%) |
| Event | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 1/309 | 0/313 |
| Event | Gepotidacin | Ceftriaxone Plus Azithromycin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 151/309 | 30/313 |
| NauseaGastrointestinal disorders | 73/309 | 9/313 |
| VomitingGastrointestinal disorders | 20/309 | 2/313 |
| FlatulenceGastrointestinal disorders | 20/309 | 1/313 |
| Abdominal PainGastrointestinal disorders | 16/309 | 3/313 |
| Faeces softGastrointestinal disorders | 16/309 | 1/313 |
| DizzinessNervous system disorders | 16/309 | 2/313 |
| Chlamydial infectionInfections and infestations | 12/309 | 10/313 |
| HeadacheNervous system disorders | 10/309 | 8/313 |
| FatigueGeneral disorders | 8/309 | 0/313 |
| Age, Continuous(Years) | Gepotidacin | Ceftriaxone Plus Azithromycin | Total |
|---|---|---|---|
| Mean | 33.9 ± 10.42 | 33.7 ± 10.70 | 33.8 ± 10.56 |
| Sex: Female, Male(Participants) | Gepotidacin | Ceftriaxone Plus Azithromycin | Total |
|---|---|---|---|
| Female | 35 | 34 | 69 |
| Male | 279 | 280 | 559 |
| Race (NIH/OMB)(Participants) | Gepotidacin | Ceftriaxone Plus Azithromycin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 10 | 19 |
| Asian | 12 | 17 | 29 |
| Native Hawaiian or Other Pacific Islander | 7 | 2 | 9 |
| Black or African American | 49 | 39 | 88 |
| White | 231 | 241 | 472 |
| More than one race | 6 | 5 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Oct 2019 to primary completion in Oct 2023, 47 months.
Results were first posted in May 2024, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin